Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 23;3(1):2055217317700668.
doi: 10.1177/2055217317700668. eCollection 2017 Jan-Mar.

Access and barriers to MS care in Latin America

Víctor M Rivera  1 , Miguel Angel Macias  2
Affiliations
Review

Access and barriers to MS care in Latin America

Víctor M Rivera et al. Mult Scler J Exp Transl Clin. .

Abstract

Multiple sclerosis (MS), an epidemiologically emergent disorder in Latin America (LATAM), poses substantial socioeconomic challenges to a region where most countries remain as economies in development. MS is not health priority despite its economic and communitarian impact with a relatively low prevalence. MS treatments in LATAM have evolved from earlier long-term oral steroids and immunosuppression protocols, to platform disease modifying therapies (DMTs), to the current landscape with more advanced therapeutic molecules. Following FDA approval, a DMT may eventually become available in LATAM conditioned to industrial marketing interest. Most countries do not count all medications in their armamentarium. Access to therapy by the MS population in the region is low (9.5%-42.8%). Generic treatments, biosimilars, and follow-on complex non-biological drugs (CNBD) are commonly available in institutional formularies in LATAM despite their lack of supportive efficacy and safety data and reported molecular differences with the innovators. Savings to health systems thus far have been negligible. Medicine licensing agencies in LATAM, despite limitations in resources, have considerably improved their assessments by incorporating more modern criteria and methodology. Access to symptomatic management, rehabilitation procedures, and the role of patients associations are discussed.

Keywords: Latin America; Multiple sclerosis; access to therapy; healthcare.

PubMed Disclaimer

References

    1. Trisolini M, Honeycut A, Wiener J, et al. Global economic impact of multiple sclerosis. London: Multiple Sclerosis International Federation (MSIF), www.msif.org/about-us/advocacy/global-economic-impact-of-ms/ (2010, accessed 16 January 2017).
    1. Kesselheim AAS, Avorn J, Sarptwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016; 316: 858–871. - PubMed
    1. Alter M, Olivares L. Multiple sclerosis in Mexico: an epidemiologic study. Arch Neurol 1970; 23: 451–454. - PubMed
    1. Rivera VM. Clinical course in patients with multiple sclerosis treated with long-term intermittent steroid and immunosuppressive therapy. In: 2nd congress of the International Rehabilitation Medicine Association, Mexico City, 27 October 1974. Basel: EULAR Publishers.
    1. Rivera VM, Breitbach W, Baralt T, et al. Chronic periodic intravenous cyclophosphamide in progressive multiple sclerosis. Neurology 1988; 38(Suppl 1): PP298.

LinkOut - more resources